**Peking University Health Science Center**
Clinical Doctorate
**Peking University Cancer Hospital & Institute**
Deputy Chief Physician, Department of Thoracic Oncology I
**Beijing Medical Award Foundation**
Secretary, Lung Cancer Youth Committee
**Chinese Society of Clinical Oncology (CSCO)**
Young Expert Committee Member
**Beijing Cancer Society**
Member, Lung Cancer Professional Committee
**National Telemedicine and Internet Medicine Center**
Standing Committee Member, Lung Cancer Professional Committee
**Beijing Health Promotion Association**
Member, Lung Cancer Diagnosis and Treatment Expert Committee
**Gerontological Society of China**
Member
**Chinese Women Doctors Association**
Member
**Principal Investigator**
Presided over 1 Wu Jieping Foundation project
**Publications (Last 5 Years)**
First/Co-first author of 9 SCI papers, cumulative impact factor >60
**Awards**
- Fifth "35 under 35" Outstanding Young Oncologist
- Champion, "Hundred Cases Soaring" Lung Cancer Immunotherapy Case Challenge
- Champion, "Jingcai Feiyang" Lung Cancer Case Challenge
**Publications**
**English Articles**
1. Minglei Zhuo*, Yanfang Guan*, Xue Yang*, et al. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma, *Clinical Cancer Research*, 2020.2.
2. Zhou X*, Jiang J*, Yang X*, et al. First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET. *J Nucl Med*. 2022 Apr;63(4):536-542.
3. Irfan C, Yang X*, et al. ALK-TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. *Crit Rev Oncol Hematol*. 2022 Dec;180:103847.
4. Zhang T, Yang X, Zhao J, et al. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. *Front. Oncol*. 2021 Jun 4;11:690093.
5. Yang X, Xia Y, Xu L, et al. Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study. *Front. Mol. Biosci*. 2021, 8:639892.
6. Xue Yang, Huang Chuan, Rongrong Chen, et al. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation, *Clin Lung Cancer*. 2020 Jul;21(4):e258-e260.
7. Xue Yang, Minglei Zhuo, Anhui Shi, et al. Optimal first-line treatment for advanced thymic carcinoma, *Thorac Cancer*. 2019 Nov;10(11):2081-2087.
8. Huang C, Yang X. Simultaneous tongue metastasis from malignant pleural mesothelioma: Case report and literature review. *Thorac Cancer*. 2020 Dec 1;12(3):391-396.
**Chinese Articles**
1. Yang Xue, Zhao Jun. Clinical Research Progress on the Treatment of EGFR Exon 20 Insertion Mutation-Positive NSCLC. *Chinese Journal of Lung Cancer*, 2022, 25(5):337-350.
2. Yang Xue, Zhao Jun, et al. Progress in Individualized Treatment of Non-Small Cell Lung Cancer. *Chinese Journal of Lung Cancer*. 2022, 25(3):C1-18.
3. Yang Xue, Zhao Jun. Discussion on Targeted Therapy Strategies for a Patient with EGFR-Mutant Advanced Non-Small Cell Lung Cancer. *Chinese Journal of Clinical Oncology*, 2021, 48(10):3.
4. Huang Chuan, Yang Xue. Research Progress on Biomarkers for Immunotherapy in Non-Small Cell Lung Cancer. *Chinese Journal of Lung Cancer*, 2021, 24(11):7.
5. Yang Xue; Chen Hanxiao; Zhang Hong, et al. Analysis of Rare EGFR Mutations in NSCLC and Preliminary Observation of EGFR-TKI Efficacy. *Chinese Journal of Lung Cancer*, 2015.8, 18(08):493~499.
English
